BioCardia, Inc. (BCDA)
NASDAQ: BCDA · IEX Real-Time Price · USD
+0.018 (5.85%)
At close: May 23, 2024, 4:00 PM
+0.003 (0.76%)
Pre-market: May 24, 2024, 9:05 AM EDT

Company Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.

Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.

The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome.

In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths.

BioCardia, Inc. is based in Sunnyvale, California.

BioCardia, Inc.
BioCardia logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Dr. Peter A. Altman Ph.D.

Contact Details

320 Soquel Way
Sunnyvale, California 94085
United States
Phone 650-226-0123

Stock Details

Ticker Symbol BCDA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000925741
CUSIP Number 09060U507
ISIN Number US09060U5074
Employer ID 23-2753988
SIC Code 2836

Key Executives

Name Position
Dr. Peter A. Altman Ph.D. Chief Executive Officer, President and Director
David McClung Chief Financial Officer
Edward M. Gillis Senior Vice President of Devices
Dr. Sujith Shetty MBBS Chief Medical Officer and Vice President of Clinical and Regulatory

Latest SEC Filings

Date Type Title
May 21, 2024 8-K Current Report
May 14, 2024 8-K Current Report
May 14, 2024 10-Q Quarterly Report
May 1, 2024 8-K Current Report
Apr 15, 2024 DEF 14A Other definitive proxy statements
Apr 5, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Apr 4, 2024 PRE 14A Other preliminary proxy statements
Apr 1, 2024 EFFECT Notice of Effectiveness
Mar 27, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 27, 2024 8-K Current Report